2 weeks Ago By ABMN Staff
Strategic Blueprint LLC trimmed its stake in IQVIA Holdings Inc. ( NYSE:IQV – Free Report ) by 14.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 2,869 shares of the medical research company’s stock after selling 493 shares during the period. Strategic Blueprint LLC’s holdings in IQVIA were worth $607,000 at the end of the most recent quarter. A number of other hedge funds have also recently modified their holdings of IQV.
Norges Bank purchased a new position in shares of IQVIA in the 4th quarter valued at $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in IQVIA by 339.6% during the 4th quarter.
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after purchasing an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC grew its position in IQVIA by 96.9% during the 4th quarter.
Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after purchasing an additional 606,333 shares during the last quarter. Capital Research Global Investors grew its position in IQVIA by 42.2% during the 4th quarter.
Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after purchasing an additional 592,372 shares during the last quarter. Finally, Cadian Capital Management LP purchased a new position in IQVIA during the 4th quarter worth $70,108,000. 89.
62% of the stock is owned by hedge funds and other institutional investors. IQVIA Stock Up 1.3 % Shares of NYSE IQV opened at $250.
81 on Friday. The company has a quick ratio of 0.85, a current ratio of 0.
85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc.
has a 52 week low of $167.42 and a 52 week high of $261.73.
The firm has a 50-day moving average price of $229.89 and a 200 day moving average price of $233.85.
The stock has a market capitalization of $45.70 billion, a price-to-earnings ratio of 34.26, a price-to-earnings-growth ratio of 2.
26 and a beta of 1.49. Analyst Upgrades and Downgrades Several brokerages have issued reports on IQV.
The Goldman Sachs Group began coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective on the stock.
Morgan Stanley raised their price objective on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd.
Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th.
Argus raised shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Barclays lifted their target price on shares of IQVIA from $255.00 to $275.
00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $265.
67. Read Our Latest Research Report on IQV Insider Activity at IQVIA In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.
33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.
88. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Company insiders own 1.
60% of the company’s stock. IQVIA Profile ( Free Report ) IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. ( NYSE:IQV – Free Report ).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter ..
